Yungpo Bernard Su - Concepedia

Author

Yungpo Bernard Su

Memorial Sloan Kettering Cancer Center

Also Known As

Yungpo Bernard Su, Yungpo Su

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Peter MacCallum Cancer Centre Nebraska Cancer Specialists The University of Melbourne Cornell University

About

Yungpo Bernard Su is an author at Memorial Sloan Kettering Cancer Center specializing in cancer therapeutics, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	3.2K
2	Cancer Therapeutics	3	3	3.2K
3	Health Sciences	1	1	53
4	Pathology	1	1	3K
5	Surgical Oncology	1	1	90

Yungpo Bernard Su

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Barbara Burtness, Kevin J. Harrington, Richard Greil, The Lancet Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck Cancer	2019	3K
Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm David G. Pfister, Yungpo Bernard Su, Dennis H. Kraus, Journal of Clinical Oncology	2006	298
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium Manish A. Shah, Yelena Y. Janjigian, Ronald G. Stoller, Journal of Clinical Oncology	2015	176
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study Neil D. Gross, David M. Miller, Nikhil I. Khushalani, The Lancet Oncology Surgical OncologySurvival OutcomesNeoadjuvant CemiplimabMedicineSurgery	2023	90
Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma Eric J. Sherman, Yungpo Bernard Su, Ashima Lyall, Thyroid	2012	67
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors Matthew G. Fury, David B. Solit, Yungpo Bernard Su, Cancer Chemotherapy and Pharmacology OncologyMetronomic TherapyAdvanced Solid TumorsPharmacotherapyFixed-dose Docetaxel	2006	53
Double-Blind, Placebo-Controlled, Randomized Trial of Granulocyte-Colony Stimulating Factor During Postoperative Radiotherapy for Squamous Head and Neck Cancer Yungpo Bernard Su, Andrew J. Vickers, Michael J. Zeléfsky, The Cancer Journal	2006	36
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma Danny Rischin, Sandro Porceddu, Fiona Day, New England Journal of Medicine	2025	36
Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706). Eric J. Sherman, Nathan R. Foster, Yungpo Bernard Su, Journal of Clinical Oncology	2021	13

Page 1